Nafarelin acetate hydrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100655

CAS#: 86220-42-0 (acetate)

Description: Nafarelin is a gonadotropin-releasing hormone agonist (GnRH agonist) which acts as an analog of GnRH. Nafarelin increases the release of FSH and LH by the anterior pituitary, which in turn leads to an increase of estrogen/progesterone. When administered, Nafarelin has the purpose of causing increase estrogen that will negatively feed back upon hypothalamus to decrease GnRH ( negative feedback loop ) Through negative feedback, Nafarelin causes a decrease in pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Nafarelin may be used in the treatment of estrogen-dependent conditions (such as endometriosis or uterine fibroids), to treat central precocious puberty, and to control ovarian stimulation in IVF. It is normally delivered via a nasal spray. Nafarelin acetate is marketed by Searle (now part of Pfizer) under the brand name Synarel.

Chemical Structure

Nafarelin acetate hydrate
CAS# 86220-42-0 (acetate)

Theoretical Analysis

MedKoo Cat#: 100655
Name: Nafarelin acetate hydrate
CAS#: 86220-42-0 (acetate)
Chemical Formula: C68H89N17O16
Exact Mass:
Molecular Weight: 1400.563
Elemental Analysis: C, 58.32; H, 6.41; N, 17.00; O, 18.28

Price and Availability

Size Price Availability Quantity
1.0g USD 2750.0 2 Weeks
2.0g USD 3950.0 2 Weeks
5.0g USD 5950.0 2 Weeks
Bulk inquiry

Related CAS #: 86220-42-0 (acetate)   76932-56-4 (free base)  

Synonym: RS-94991-298; Nafarelin acetate; Nafarelin acetate hydrate; Synarel

IUPAC/Chemical Name: Pyr-His-Trp-Ser-Tyr-D-2-Nal-Leu-Arg-Pro-Gly-NH2 acetate hydrate


InChi Code: InChI=1S/C66H83N17O13.C2H4O2.H2O/c1-36(2)25-48(58(89)76-47(13-7-23-71-66(68)69)65(96)83-24-8-14-54(83)64(95)73-33-55(67)86)77-60(91)50(28-38-15-18-39-9-3-4-10-40(39)26-38)78-59(90)49(27-37-16-19-43(85)20-17-37)79-63(94)53(34-84)82-61(92)51(29-41-31-72-45-12-6-5-11-44(41)45)80-62(93)52(30-42-32-70-35-74-42)81-57(88)46-21-22-56(87)75-46;1-2(3)4;/h3-6,9-12,15-20,26,31-32,35-36,46-54,72,84-85H,7-8,13-14,21-25,27-30,33-34H2,1-2H3,(H2,67,86)(H,70,74)(H,73,95)(H,75,87)(H,76,89)(H,77,91)(H,78,90)(H,79,94)(H,80,93)(H,81,88)(H,82,92)(H4,68,69,71);1H3,(H,3,4);1H2/t46-,47-,48-,49-,50-,51+,52+,53-,54+;;/m1../s1

SMILES Code: CC(C[C@H](C(N[C@@H](C(N1[C@@H](CCC1)C(NCC(N)=O)=O)=O)CCCNC(N)=N)=O)NC([C@@H](CC2=CC=C3C=CC=CC3=C2)NC([C@@H](CC4=CC=C(C=C4)O)NC([C@@H](CO)NC([C@H](CC5=CNC6=C5C=CC=C6)NC([C@H](CC7=CNC=N7)NC([C@H](N8)CCC8=O)=O)=O)=O)=O)=O)=O)C.CC(O)=O.[H]O[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 1400.563 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

     1: Ludwig C, Desmoulins PO, Driancourt MA, Goericke-Pesch S, Hoffmann B. Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin as a removable implant "Gonazon"; a preclinical trial. Theriogenology. 2009 Apr 15;71(7):1037-45. doi: 10.1016/j.theriogenology.2008.10.015. Epub 2009 Feb 23. PubMed PMID: 19233456.

2: Cheng MH, Yu BK, Chang SP, Wang PH. A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. J Chin Med Assoc. 2005 Jul;68(7):307-14. PubMed PMID: 16038370.

3: Raiman J, Koljonen M, Huikko K, Kostiainen R, Hirvonen J. Delivery and stability of LHRH and Nafarelin in human skin: the effect of constant/pulsed iontophoresis. Eur J Pharm Sci. 2004 Feb;21(2-3):371-7. PubMed PMID: 14757511.

4: Suh J, Lee E, Hwang S, Yoon S, Yoon BK, Bae D, Choi D. Dose of GnRH agonist (nafarelin acetate) affects intrafollicular PAPP-A expression in controlled ovarian hyperstimulation cycle. Eur J Obstet Gynecol Reprod Biol. 2004 Jan 15;112(1):65-8. PubMed PMID: 14687742.

5: Jiménez-Severiano H, D'Occhio MJ, Lunstra DD, Mussard ML, Koch JW, Ehnis LR, Enright WJ, Kinder JE. Effect of chronic treatment with the gonadotrophin-releasing hormone agonist azagly-nafarelin on basal concentrations of LH in prepubertal bulls. Reproduction. 2003 Feb;125(2):225-32. PubMed PMID: 12578536.

6: Franco JG Jr, Baruffi RL, Mauri AL, Petersen CG, Chufallo JE, Felipe V, Garbellini E. Prospective randomized comparison of ovarian blockade with nafarelin versus leuprolide during ovarian stimulation with recombinant FSH in an ICSI program. J Assist Reprod Genet. 2001 Nov;18(11):593-7. PubMed PMID: 11804427; PubMed Central PMCID: PMC3455697.

7: Heinig J, Coenen-Worch V, Cirkel U. Acute exacerbation of chronic maxillary sinusitis during therapy with nafarelin nasal spray. Eur J Obstet Gynecol Reprod Biol. 2001 Dec 1;99(2):266-7. PubMed PMID: 11788185.

8: Takeuchi S, Minoura H, Shibahara T, Tsuiki Y, Noritaka F, Toyoda N. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril. 2001 Sep;76(3):532-7. PubMed PMID: 11532477.

9: Palatyński A, Gruszczyńska J, Sobkiewicz S. [Nafarelin acetate (Synarel) and thermocoagulation in the treatment of endometriosis]. Ginekol Pol. 2001 May;72(5):284-9. Polish. PubMed PMID: 11526758.

10: Brett S, Yong PY, Thong KJ. Ovarian hyperstimulation after the sole use of a gonadotrophin-releasing hormone agonist (Nafarelin) as a complication of in vitro fertilisation treatment. J Assist Reprod Genet. 2001 Jun;18(6):353-6. PubMed PMID: 11495415; PubMed Central PMCID: PMC3455846.

11: Bergqvist A; SCANDET Group. A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis. Gynecol Endocrinol. 2000 Dec;14(6):425-32. PubMed PMID: 11228063.

12: Wong JM, Forrest KA, Snabes SZ, Zhao SZ, Gersh GE, Kennedy SH. Efficacy of nafarelin in assisted reproductive technology: a meta-analysis. Hum Reprod Update. 2001 Jan-Feb;7(1):92-101. PubMed PMID: 11212082.

13: McNulty SJ, Hardy KJ. Two patients with acute intermittent porphyria treated with nafarelin to prevent menstrual exacerbations. J R Soc Med. 2000 Aug;93(8):429-30. PubMed PMID: 10983507; PubMed Central PMCID: PMC1298087.

14: Minaguchi H, Wong JM, Snabes MC. Clinical use of nafarelin in the treatment of leiomyomas. A review of the literature. J Reprod Med. 2000 Jun;45(6):481-9. Review. PubMed PMID: 10900582.

15: Kurabayashi T, Takakuwa K, Tanaka K. Treatment with nafarelin for endometriosis in young women. Efficacy, safety and lipid metabolism. Niigata Nafarelin Study Group. J Reprod Med. 2000 Jun;45(6):454-60. PubMed PMID: 10900577.

16: Sánchez Contreras J, Hernández Vivar LE, Villalobos Cid MA, Risco Cortés RJ. [Conservative treatment of interstitial ectopic pregnancy and endometriosis with laparoscopic methotrexate and potassium chloride and complementary management with nasal nafarelin. Report of a case and review of the literature]. Ginecol Obstet Mex. 2000 Jan;68:35-8. Review. Spanish. PubMed PMID: 10774100.

17: Calvo Lugo GE, Sauceda González LF, Jiménez Perea ML, Díaz Arias FJ. [Treatment of pelvic endometriosis with goserelin acetate or nafarelin acetate. Comparative study]. Ginecol Obstet Mex. 2000 Jan;68:7-14. Spanish. PubMed PMID: 10774095.

18: Nakao A, Iwagaki H, Kanagawa T, Jikuhara A, Matsubara N, Takakura N, Isozaki H, Tanaka N. Crohn's disease mimicking as bowel endometriosis. Are the symptoms reduced by nafarelin acetate? Arch Gynecol Obstet. 2000 Feb;263(3):131-3. PubMed PMID: 10763842.

19: Tahara M, Matsuoka T, Yokoi T, Tasaka K, Kurachi H, Murata Y. Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy). Fertil Steril. 2000 Apr;73(4):799-804. PubMed PMID: 10731543.

20: Loh SK, Leong NK. Nafarelin acetate for pituitary suppressions in in-vitro fertilisation cycles--a Singaporean experience. Singapore Med J. 1999 Dec;40(12):752-5. PubMed PMID: 10709427.

Additional Information